Nordeoxycholic Acid是一种疏水性胆汁酸代谢物，可作为LC-MS/MS测定中相关代谢物检测的模型化合物。
Cas No.:53608-86-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Nordeoxycholic Acid, a hydrophobic bile acid metabolite, acts as a model compound in LC-MS/MS measurement for the related metabolite detection [1]. Nordeoxycholic acid forms three kinds of host frameworks, M1, M2, and M3, with channels where aliphatic alcohols are accommodated [2]. Nordeoxycholic acid can be used as an indicator to assist in the diagnosis of calcific aortic valve stenosis (CAVS) [3]. Nordeoxycholic acid acts a diagnostic biomarker for acute pancreatitis (AP)[4].
In vivo, Nordeoxycholic Acid treatment via oral gavage at a dose of 125mg/kg/day for 5 days induced extensive hepatic inflammation and live damage in mice[5].
References:
[1] Cao Y, Niu X, Li W, et al. Structural identification of in vitro metabolites for 23-nordeoxycholic acid by structural analogue matching[J]. Analytical Methods, 2023, 15(21): 2588-2598..
[2] Kato K, Aoki Y, Sugahara M, et al. Interpretation of enantioresolution in nordeoxycholic acid channels based on the four‐location model[J]. Chirality: The Pharmacological, Biological, and Chemical Consequences of Molecular Asymmetry, 2003, 15(1): 53-59.
[3] Atefi N, Surendran A, Raabe M, et al. Role of Bile Acids in Calcific Aortic Valve Stenosis[J]. Circulation, 2021, 144(Suppl_1): A9316-A9316.
[4] Liu X, Yu J, Liu J, et al. Norcholic Acid Promotes M1 Macrophage Polarization in Acute Pancreatitis by Activating the Wnt/β-Catenin Pathway[J]. Frontiers in Bioscience-Landmark, 2025, 30(6): 39259.
[5] Guo W, Zhong W, He L, et al. Reversal of hepatic accumulation of nordeoxycholic acid underlines the beneficial effects of cholestyramine on alcohol-associated liver disease in mice[J]. Hepatology Communications, 2024, 8(8): e0507.
Nordeoxycholic Acid是一种疏水性胆汁酸代谢物，可作为LC-MS/MS测定中相关代谢物检测的模型化合物[1]。Nordeoxycholic Acid可形成三种主-客体结构框架（M1、M2和M3），其中的通道能够容纳脂肪醇[2]。Nordeoxycholic Acid可作为辅助诊断钙化性主动脉瓣狭窄（CAVS）的指标[3]。Nordeoxycholic Acid是急性胰腺炎（AP）的诊断性生物标志物[4]。
在体内，以每日125mg/kg的剂量通过口服灌胃给予Nordeoxycholic Acid，持续5天，可诱导小鼠出现广泛的肝脏炎症和肝损伤[5]。
| Animal experiment [1]: | |
Animal models | Male C57BL/6J mice |
Preparation Method | Eight-week-old male C57BL/6J mice were raised in a standard sterile environment and had free access to food and water. Male C57BL/6J mice were given cholic acid (CA), lithocholic acid (LCA), or Nordeoxycholic Acid by gavage at a dose of 125mg/kg/day for 5 days. The mice's livers were then collected for analysis. |
Dosage form | 125mg/kg/day; p.o. |
Applications | Nordeoxycholic Acid treatment induced extensive hepatic inflammation and live damage in mice. |
References: | |
| Cas No. | 53608-86-9 | SDF | |
| 别名 | 去甲脱氧氯酸,23-NDCA, 23-Nordeoxycholic Acid | ||
| 化学名 | (3α,5β,12α)- 3,12- dihydroxy-24- norcholan -23- oic acid | ||
| Canonical SMILES | C[C@H](CC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])CC[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@@]21C | ||
| 分子式 | C23H38O4 | 分子量 | 378.6 |
| 溶解度 | DMF: 15mg/mL,DMF:PBS (pH 7.2) (1:4): 0.2mg/mL,DMSO: 10mg/mL,Ethanol: 10mg/mL | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6413 mL | 13.2066 mL | 26.4131 mL |
| 5 mM | 528.3 μL | 2.6413 mL | 5.2826 mL |
| 10 mM | 264.1 μL | 1.3207 mL | 2.6413 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet